Cadrenal Therapeutics Inc... (CVKD)
17.43
-1.57 (-8.26%)
At close: Mar 03, 2025, 3:59 PM
17.40
-0.17%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 16.01 |
| Market Cap | 31.07M |
| Revenue (ttm) | 4.47K |
| Net Income (ttm) | -12.28M |
| EPS (ttm) | -6.73 |
| PE Ratio (ttm) | -2.59 |
| Forward PE | -4.44 |
| Analyst | Strong Buy |
| Ask | 20 |
| Volume | 58,686 |
| Avg. Volume (20D) | 57,682 |
| Open | 18.10 |
| Previous Close | 19.00 |
| Day's Range | 16.81 - 18.71 |
| 52-Week Range | 5.40 - 22.90 |
| Beta | 1.41 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CVKD
Website https://www.cadrenal.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 83.59% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago
+17.97%
Cadrenal Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
